BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Majidpoor J, Mortezaee K. Angiogenesis as a hallmark of solid tumors - clinical perspectives. Cell Oncol (Dordr) 2021;44:715-37. [PMID: 33835425 DOI: 10.1007/s13402-021-00602-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 38.0] [Reference Citation Analysis]
Number Citing Articles
1 Mark J, Fisher DT, Kim M, Emmons T, Khan AN, Alqassim E, Singel K, Mistarz A, Lugade A, Zhan H, Yu H, Segal B, Lele S, Frederick P, Kozbor D, Skitzki J, Odunsi K. Carboplatin enhances lymphocyte-endothelial interactions to promote CD8+ T cell trafficking into the ovarian tumor microenvironment. Gynecologic Oncology 2023;168:92-99. [DOI: 10.1016/j.ygyno.2022.11.001] [Reference Citation Analysis]
2 Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
3 Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomedicine & Pharmacotherapy 2022;156:113906. [DOI: 10.1016/j.biopha.2022.113906] [Reference Citation Analysis]
4 Zalpoor H, Aziziyan F, Liaghat M, Bakhtiyari M, Akbari A, Nabi-afjadi M, Forghaniesfidvajani R, Rezaei N. The roles of metabolic profiles and intracellular signaling pathways of tumor microenvironment cells in angiogenesis of solid tumors. Cell Commun Signal 2022;20:186. [DOI: 10.1186/s12964-022-00951-y] [Reference Citation Analysis]
5 Qiu Y, Chen Y, Agbede O, Eshaghi E, Peng C. Circular RNAs in Epithelial Ovarian Cancer: From Biomarkers to Therapeutic Targets. Cancers 2022;14:5711. [DOI: 10.3390/cancers14225711] [Reference Citation Analysis]
6 Yang C, Zhang H, Zhang L, Zhu AX, Bernards R, Qin W, Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [DOI: 10.1038/s41575-022-00704-9] [Reference Citation Analysis]
7 Zamborlin A, Voliani V. Gold nanoparticles as antiangiogenic and antimetastatic agents. Drug Discovery Today 2022. [DOI: 10.1016/j.drudis.2022.103438] [Reference Citation Analysis]
8 Chiangjong W, Chutipongtanate S. EV-out or EV-in: Tackling cell-to-cell communication within the tumor microenvironment to enhance anti-tumor efficacy using extracellular vesicle-based therapeutic strategies. OpenNano 2022;8:100085. [DOI: 10.1016/j.onano.2022.100085] [Reference Citation Analysis]
9 Zhang G, Xu Z, Zheng J, Wang M, Ren J, Wei X, Huan Y, Zhang J. Prognostic value of multi b-value DWI in patients with locally advanced rectal cancer. Eur Radiol 2022. [PMID: 36219237 DOI: 10.1007/s00330-022-09159-7] [Reference Citation Analysis]
10 Mortezaee K, Majidpoor J. Extracellular vesicle-based checkpoint regulation and immune state in cancer. Med Oncol 2022;39:225. [PMID: 36175741 DOI: 10.1007/s12032-022-01837-2] [Reference Citation Analysis]
11 Li X, Fan Y, Tang M, Li H, Zhang Y, Mi J, Wang Y, Zhao M, Wang Z, Su F. PLXDC1 Can Be a Biomarker for Poor Prognosis and Immune Evasion in Gastric Cancer. J Inflamm Res 2022;15:5439-55. [PMID: 36147688 DOI: 10.2147/JIR.S383191] [Reference Citation Analysis]
12 Ding K, Liu X, Wang L, Zou L, Jiang X, Li A, Zhou J. Targeting JWA for Cancer Therapy: Functions, Mechanisms and Drug Discovery. Cancers 2022;14:4655. [DOI: 10.3390/cancers14194655] [Reference Citation Analysis]
13 Sanati M, Afshari AR, Amini J, Mollazadeh H, Jamialahmadi T, Sahebkar A. Targeting angiogenesis in gliomas: Potential role of phytochemicals. Journal of Functional Foods 2022;96:105192. [DOI: 10.1016/j.jff.2022.105192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Xu M, Fan R, Fan X, Shao Y, Li X. Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis. DDDT 2022;Volume 16:3241-3262. [DOI: 10.2147/dddt.s383101] [Reference Citation Analysis]
15 Chen Z, Mou Y, Zhong H, Xu J, Zhang X, Li G, He J, Zhang W, Huang W, Tian H. Cassaine diterpenoids from the seeds of Erythrophleum fordii Oliv. and their anti-angiogenic activity. Phytochemistry 2022;:113399. [PMID: 36027967 DOI: 10.1016/j.phytochem.2022.113399] [Reference Citation Analysis]
16 He J, Liu Z, Zhu X, Xia H, Gao H, Lu J. Ultrasonic Microbubble Cavitation Enhanced Tissue Permeability and Drug Diffusion in Solid Tumor Therapy. Pharmaceutics 2022;14:1642. [PMID: 36015267 DOI: 10.3390/pharmaceutics14081642] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Liao Y, Wu X, Wu M, Fang Y, Li J, Tang W. Non-coding RNAs in lung cancer: emerging regulators of angiogenesis. J Transl Med 2022;20:349. [PMID: 35918758 DOI: 10.1186/s12967-022-03553-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Salama MM, Zaghloul RA, Khalil RM, El-shishtawy MM. Sitagliptin Potentiates the Anti-Neoplastic Activity of Doxorubicin in Experimentally-Induced Mammary Adenocarcinoma in Mice: Implication of Oxidative Stress, Inflammation, Angiogenesis, and Apoptosis. Sci Pharm 2022;90:42. [DOI: 10.3390/scipharm90030042] [Reference Citation Analysis]
19 Mortezaee K, Majidpoor J. Dysregulated metabolism: A friend-to-foe skewer of macrophages. International Reviews of Immunology. [DOI: 10.1080/08830185.2022.2095374] [Reference Citation Analysis]
20 Zaki I, Masoud RE, Hamoud MM, Ali OAA, Abualnaja M, Fayad E, Almaaty AHA, Elnaghia LK. Design, synthesis and cytotoxicity screening of new synthesized pyrimidine-5-carbonitrile derivatives showing marked apoptotic effect. Journal of Molecular Structure 2022;1259:132749. [DOI: 10.1016/j.molstruc.2022.132749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Bisht S, Nigam M, Kunjwal SS, Sergey P, Mishra AP, Sharifi-rad J, Sorrenti V. Cancer Stem Cells: From an Insight into the Basics to Recent Advances and Therapeutic Targeting. Stem Cells International 2022;2022:1-28. [DOI: 10.1155/2022/9653244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Scherbakov AM, Fetisov TI, Sorokin DV, Zinovieva VY, Moiseeva NI, Laletina LA, Kirilin EM, Manikaylo AE, Fomina LY, Mekheda LV, Bokhyan BY, Lesovaya EA, Trukhanova LS, Gor’kova TG, Antoshina EE, Morozova OV, Kirsanov KI, Yakubovskaya MG. Hypoxia-related proteins VEGF A and CA IX and resistance of soft tissue sarcoma cells to chemotherapy: <i>ex vivo</i> pilot study. Usp mol onkol 2022;9:58-65. [DOI: 10.17650/2313-805x-2022-9-2-58-65] [Reference Citation Analysis]
23 Sharifi M, Cho WC, Ansariesfahani A, Tarharoudi R, Malekisarvar H, Sari S, Bloukh SH, Edis Z, Amin M, Gleghorn JP, Hagen TLMT, Falahati M. An Updated Review on EPR-Based Solid Tumor Targeting Nanocarriers for Cancer Treatment. Cancers (Basel) 2022;14:2868. [PMID: 35740534 DOI: 10.3390/cancers14122868] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
24 Xu Y, Cao C, Zhu Z, Wang Y, Tan Y, Xu X. Novel Hypoxia-Associated Gene Signature Depicts Tumor Immune Microenvironment and Predicts Prognosis of Colon Cancer Patients. Front Genet 2022;13:901734. [DOI: 10.3389/fgene.2022.901734] [Reference Citation Analysis]
25 Masuda N, Ono M, Mukohara T, Yasojima H, Shimoi T, Kobayashi K, Harano K, Mizutani M, Tanioka M, Takahashi S, Kogawa T, Suzuki T, Okumura S, Takase T, Nagai R, Semba T, Zhao Z, Ren M, Yonemori K. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort. European Journal of Cancer 2022;168:108-18. [DOI: 10.1016/j.ejca.2022.03.004] [Reference Citation Analysis]
26 Giuli MV, Mancusi A, Giuliani E, Screpanti I, Checquolo S. Notch signaling in female cancers: a multifaceted node to overcome drug resistance. Cancer Drug Resist 2021;4:805-36. [PMID: 35582386 DOI: 10.20517/cdr.2021.53] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Mortezaee K, Majidpoor J. CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives. Front Immunol 2022;13:864298. [DOI: 10.3389/fimmu.2022.864298] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
28 Zhang P, Qin C, Liu N, Zhou X, Chu X, Lv F, Gu Y, Yin L, Liu J, Zhou J, Huo M. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. Biomaterials 2022. [DOI: 10.1016/j.biomaterials.2022.121518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
29 Mortezaee K, Majidpoor J. Checkpoint inhibitor/interleukin-based combination therapy of cancer. Cancer Med 2022. [PMID: 35301813 DOI: 10.1002/cam4.4659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
30 Welsh M. Perspectives on Vascular Regulation of Mechanisms Controlling Selective Immune Cell Function in the Tumor Immune Response. Int J Mol Sci 2022;23:2313. [PMID: 35216427 DOI: 10.3390/ijms23042313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yu DL, Lou ZP, Ma FY, Najafi M. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol 2022;105:108555. [PMID: 35121223 DOI: 10.1016/j.intimp.2022.108555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
32 Elemam NM, Malek AI, Mahmoud EE, El-huneidi W, Talaat IM. Insights into the Role of Gremlin-1, a Bone Morphogenic Protein Antagonist, in Cancer Initiation and Progression. Biomedicines 2022;10:301. [DOI: 10.3390/biomedicines10020301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Mortezaee K, Majidpoor J. (Im)maturity in Tumor Ecosystem. Front Oncol 2022;11:813897. [DOI: 10.3389/fonc.2021.813897] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
34 Fan B, Li Q, Jiang Y, Shen W, Xing Y, Liang G, Wu Q, Ban S, Zhang R. Development of carrier-free nanodrugs based on low molecular weight heparin–doxorubicin conjugate assembly with smart pH-triggered drug release characteristics for combinatorial antitumor therapy. New J Chem 2022;46:820-31. [DOI: 10.1039/d1nj04224f] [Reference Citation Analysis]
35 Morbidelli L. General conclusions and future perspectives. Antiangiogenic Drugs as Chemosensitizers in Cancer Therapy 2022. [DOI: 10.1016/b978-0-323-90190-1.00004-4] [Reference Citation Analysis]
36 Roy R, Man E, Aldakhlallah R, Rashes E, Moses MA. The Tumor and Its Microenvironment as Complementary Sources of Cancer Biomarkers. Biomarkers of the Tumor Microenvironment 2022. [DOI: 10.1007/978-3-030-98950-7_22] [Reference Citation Analysis]
37 Nitzsche B, Rong WW, Goede A, Hoffmann B, Scarpa F, Kuebler WM, Secomb TW, Pries AR. Coalescent angiogenesis-evidence for a novel concept of vascular network maturation. Angiogenesis 2021. [PMID: 34905124 DOI: 10.1007/s10456-021-09824-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Cocola C, Magnaghi V, Abeni E, Pelucchi P, Martino V, Vilardo L, Piscitelli E, Consiglio A, Grillo G, Mosca E, Gualtierotti R, Mazzaccaro D, La Sala G, Di Pietro C, Palizban M, Liuni S, DePedro G, Morara S, Nano G, Kehler J, Greve B, Noghero A, Marazziti D, Bussolino F, Bellipanni G, D'Agnano I, Götte M, Zucchi I, Reinbold R. Transmembrane Protein TMEM230, a Target of Glioblastoma Therapy. Front Cell Neurosci 2021;15:703431. [PMID: 34867197 DOI: 10.3389/fncel.2021.703431] [Reference Citation Analysis]
39 Majidpoor J, Mortezaee K. Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomed Pharmacother 2021;145:112419. [PMID: 34781146 DOI: 10.1016/j.biopha.2021.112419] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
40 Najafi M, Majidpoor J, Toolee H, Mortezaee K. The current knowledge concerning solid cancer and therapy. J Biochem Mol Toxicol 2021;:e22900. [PMID: 34462987 DOI: 10.1002/jbt.22900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
41 Mortezaee K. Normalization in tumor ecosystem: Opportunities and challenges. Cell Biol Int 2021. [PMID: 34189798 DOI: 10.1002/cbin.11655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
42 Schoedel K, Miller V, Osei-Hwedieh D, Watters R, Duensing A, John I, Chandran U, Chang A, Soman V, Weiss K. Differential expression of angiogenesis markers HSP70, HSP90, VEGF and pERK1/2 in both components of dedifferentiated chondrosarcomas. J Bone Oncol 2021;29:100370. [PMID: 34094840 DOI: 10.1016/j.jbo.2021.100370] [Cited by in F6Publishing: 1] [Reference Citation Analysis]